Proposed Equity Fundraise - Strategic Direction

AI SummaryClose X

BSF Enterprise PLC announced a proposed £15 million equity fundraise to accelerate the commercialisation of its tissue-engineered technologies. Approximately £0.5 million will support Kerato's liquid cornea trial, which is partially funded by a Canadian government grant, aiming for veterinary market launch. The funds will also advance 3D Bio-Tissues' CytoBoost REVIVE and other cell culture media supplements, targeting the cryopreservation market. Additionally, BSF plans to allocate proceeds to strategic mergers and acquisitions to broaden its technological footprint and commercial pipeline.

Disclaimer*

UK 100

Latest directors dealings